SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
SAN
99.62
-0.56%↓
EI
248.8
-7.03%↓
SHL.DE
46.38
-7.09%↓
ARGX
535.8
+0.3%↑
FRE
39.76
+0.86%↑
24h
Current
Min
121.5
Max
126.6
Income | -142M 667M |
---|---|
Sales | 152M 5.4B |
P/E Sector Avg | 26.27 63.778 |
EPS | 2.2 |
Dividend yield | 1.34 |
Profit margin | 12.311 |
EBITDA | 85M 1.6B |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +39.46% upside |
Dividend yield Sector Avg | 1.34% 2.39% |
---|---|
Next Earnings | 15 maj 2025 |
Market Cap | 33B 98B |
---|---|
Previous open | 124.87 |
Previous close | 121.85 |
By Trading Central
Confidence
Strong Bearish Evidence
N/A / 126.35 Support & Resistance
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
6 mar 2025, 06:27 UTC
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
DJ
Read
11 lut 2025, 07:03 UTC
Germany's Merck in Talks to Buy SpringWorks Therapeutics
DJ
Read
10 lut 2025, 16:38 UTC
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
DJ
Read
6 mar 2025, 11:18 UTC
Impact from U.S. Tariffs Is Manageable for Merck KGaA, CEO Says -- Market Talk
DJ
Read
6 mar 2025, 11:14 UTC
Merck KGaA's Outlook Signals Greater Transparency -- Market Talk
DJ
Read
6 mar 2025, 08:20 UTC
Merck KGaA's Earnings Guidance Seems Soft Amid Semiconductor Uncertainty -- Market Talk
DJ
Read
6 mar 2025, 06:00 UTC
Merck KGaA Expects 2025 Net Sales Between EUR21.5B and EUR22.9B
DJ
Read
6 mar 2025, 06:00 UTC
Merck KGaA 2024 Adj EPS EUR8.63
DJ
Read
6 mar 2025, 06:00 UTC
Merck KGaA Expects 2025 EBITDA Before One-Time Items Between EUR6.1B and EUR6.6B
DJ
Read
6 mar 2025, 06:00 UTC
Merck KGaA 2024 EBIT EUR3.645B
DJ
Read
6 mar 2025, 06:00 UTC
Merck KGaA 2024 After-Tax Profit EUR2.79B
DJ
Read
6 mar 2025, 06:00 UTC
Merck KGaA 2024 Ebitda Before One-Time Items EUR6.07B
DJ
Read
6 mar 2025, 06:00 UTC
Merck KGaA 2024 EBITDA EUR5.78B
DJ
Read
6 mar 2025, 06:00 UTC
Merck KGaA 2024 Sales EUR21.16B
DJ
Read
6 mar 2025, 06:00 UTC
Merck KGaA Keeps Dividend at EUR2.20
DJ
Read
6 mar 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Sales at EUR21.14B
DJ
Read
6 mar 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Ebitda Before One-Time Items at EUR6.08B
DJ
Read
11 lut 2025, 16:45 UTC
Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk
DJ
Read
11 lut 2025, 10:54 UTC
Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk
DJ
Read
11 lut 2025, 10:52 UTC
German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk
DJ
Read
6 sty 2025, 13:08 UTC
Merck KGaA: Transaction closed on Dec. 23, 2024
DJ
Read
6 sty 2025, 13:07 UTC
Merck KGaA: Didn't Disclose Financial Details
DJ
Read
6 sty 2025, 13:06 UTC
Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio
DJ
Read
6 sty 2025, 13:04 UTC
Merck KaA Acquires HUB Organoids Holding B.V. to Expand Its Next-Generation Biology Portfolio
DJ
Read
17 gru 2024, 13:05 UTC
Merck: Deal Expected to Close By End Dec. 2024
DJ
Read
17 gru 2024, 13:04 UTC
Merck: Terms of Deal Undisclosed
DJ
Read
17 gru 2024, 13:04 UTC
Merck Signs Pact to Buy HUB Organoids
DJ
Read
17 gru 2024, 13:03 UTC
Merck: Acquisition Advances Next Gen Biology Portfolio
DJ
Read
17 gru 2024, 13:03 UTC
Merck to Buy HUB Organoids Holding
DJ
Read
14 lis 2024, 11:15 UTC
Merck KGaA's Sales Target Dragged by Muted China Outlook -- Market Talk
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 175.86 EUR 39.46%
High 190 EUR
Low 160 EUR
Based on 9 Wall Street analysts offering 12 month price targets forMerck KGaA - Dist in the last 3 months.
By TipRanks
Strong Buy
9 ratings
7
Buy
2
Hold
0
Sell
Based on 9 analysts giving stock ratings to Merck KGaA - Dist in the past 3 months.
By Trading Central
Short Term
Strong Bearish Evidence
All events are bearish.
Intermediate Term
Weak Bullish Evidence
Recent bullish events outweigh bearish events.
Long Term
Strong Bearish Evidence
All events are bearish.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$